Pegaptanib Sodium on Foveal Thickening in Patients With Exudative Subfoveal Age-Related Macular Degeneration (AMD)
This study has been completed.
First Posted: July 16, 2004
Last Update Posted: May 3, 2006
Information provided by:
The purpose of this study is to determine if Macugen™ reduces foveal thickness and improves vision in patients with wet AMD.
|Macular Degeneration||Drug: Macugen ™ (pegaptanib sodium injection)||Phase 2|
|Study Design:||Allocation: Randomized
Intervention Model: Factorial Assignment
Primary Purpose: Treatment
|Official Title:||A Phase II Prospective, Randomized, Double-Masked, Sham-Controlled, Dose-Ranging, Multi-Center Trial to Assess the Effect of Pegaptanib Sodium on Foveal Thickening in Patients With Exudative Subfoveal Age-Related Macular Degeneration (AMD)|
Resource links provided by NLM:
U.S. FDA Resources
Further study details as provided by Eyetech Pharmaceuticals:
|Study Start Date:||March 2004|
|Estimated Study Completion Date:||May 2006|
This will be a randomized, double-masked, controlled, dose-ranging, multi-center comparative trial, in parallel groups. Patients will be stratified by clinical center and foveal thickness to be treated either Macugen or a sham injection. After 24 weeks, all patients will treated with Macugen until the end of the study at 54 weeks.
Contacts and Locations
No Contacts or Locations Provided